rivey mp, allington dr, reinivaara-hall t, mathis jb ...€¦ · web viewsyncope and ischemic...

CURRICULUM VITAEMICHAEL P. RIVEY

Address: 6015 Sunview Dr. Telephone: 406-251-3369(home) Missoula, MT 59801 406-243-6796(work)

PROFESSIONAL GOALS

1. Involvement in development and execution of clinical pharmacy services.2. Participation in design and implementation of educational services to provide current

medical information concerning drug therapy.3. Participation in the investigation and documentation of issues in health care relating to

pharmacy.

EDUCATION

Master of Science in Pharmacy, Clinical and Hospital Pharmacy Division, University of Iowa, December 1982. Thesis committee: Mary J. Berg, Pharm.D., Boris A. Vern, M.D., Richard Leff, Pharm.D.

Courses: advanced therapeutics, biostatistics, clinical toxicology, epidemiology, advanced pharmacokinetics and biopharmaceutics, clinical pharmacokinetics, research methods, advanced neurology, antimicrobials, nuclear pharmacy, and thesis research.

Bachelor of Science in Pharmacy, University of Iowa, May 1974.

PROFESSIONAL EXPERIENCE

Professor, July 1998 to present. * Chair of Pharmacy Practice: November 2003 to presentAssociate Professor, July 1991 to 1998Assistant Professor, July 1984 to 1991, School of Pharmacy, University of Montana, Missoula, Montana.

Dean: David Forbes, Ph.D.1. Instructor for clinical pharmacy curriculum, including Therapeutics Sequence, and

other practice-related courses.a. Focus areas: internal medicine, anticoagulation, infectious disease

2. Residency Program Director for PGY1 residency in Pharmacy Practice2. Direction of senior students during clinical clerkship and hospital externship at

Community Medical Center, Missoula, Mt.3. Instruction in courses for Psychology graduate students, Physical Therapy students,

and Nurse Practitioner students.4. Instruction of Pharm.D. students in distance-learning external Pharm.D. program.

Clinical Consultant and Residency Program Director, April 2004 to present. Community Medical Center, Missoula, Montana.

Consultant to clinical pharmacy services in 145-bed hospital. Manager of pharmacokinetics service. Residency Program Director for pharmacy practice residency jointly sponsored by CMC and UM, and primary preceptor for that program at CMC.

Michael P. Rivey, CV

PROFESSIONAL EXPERIENCE (continued):

Clinical Coordinator, December 1984 to April 2004, Community Medical Center, Missoula, Montana.

Coordinator for clinical pharmacy services in 145-bed community hospital. Responsible for clinical program development, drug utilization review including antibiotic review, pharmacokinetic service, drug therapy monitoring service and drug information. Residency Program Director since 2001. Member of P&T, Infection Control, Physician QI, and Diabetes Task Force Committees.

Assistant Clinical Instructor, February 1984 to May 1984, University of Iowa, Iowa City, Iowa.Instructor of clinical pharmacy clerkship in adult medicine for senior pharmacy students at Veterans Administration Hospital. Maintained clinical practice in pulmonary

medicine ward and assisted with clinical nutrition team.

Clinical Pharmacy Resident (ASHP approved), January 1983 to December 1983, Veterans Administration Medical Center, Iowa City, Iowa.

Preceptors: Michael R. Alexander, M.S. and Alan Mustion, B.S.1. Pulmonary medicine, under supervision of Michael R. Alexander, M.S., 2 months

service on medical ward team; responsibilities of team included medical intensive care unit.

2. Internal medicine, under supervision of Jerry W. Taylor, Pharm.D. and Michael R. Alexander, M.S., 4 months.

3. Psychiatric service, under supervision of Bruce Alexander, Pharm.D. 2 months.4. Clinical pharmacokinetics service, under supervision of Randall A. Prince, Pharm.D.,

2 months.5. Administrative practice and projects, under supervision of Alan Mustion, B.S., 2

months.6. Clinical pharmacist in outpatient pulmonary clinic, 12 months.7. Participation in undergraduate and Pharm.D. student teaching, 9 months.8. Development of technician training lecture course.9. Assistance with clinical research projects.10. Inspection of pharmacy services at Quincy Soldiers Home.

11. Presentations to medical staff and students during staffing rounds. 12. Participation with Total Parenteral Nutrition team.

Teaching Assistant, September 1980 to July 1982, Iowa Drug Information Service (IDIS), University of Iowa, Iowa City, Iowa.

Indexed medical literature into computer-based drug information system and handled drug information requests from subscribers.

Staff Pharmacist, July 1974 to August 1980. various settings and locations.Provided services to wide spectrum of pharmacy operations including clinic, community, and hospital pharmacies.


PROFESSIONAL EXPERIENCE (continued):

Pharmacy Manager, April 1977 to March 1978, Cal-Meds, Inc., Hayward, California.Provided unit dose pharmacy services to skilled nursing facilities in San Francisco bay area; involvement in therapy consultation and review, and nursing inservice education. Preceptor to clinical rotation for senior students from University of Pacific College of Pharmacy.

Pharmacy Intern and Staff, September 1974 to May 1975, Mohave General Hospital, Kingman, Arizona.

Provided inpatient and outpatient pharmacy services, comprehensive IV admixture program, and nursing inservice education. Member of CPR team and Pharmacy and Therapeutics Committee.

PUBLICATIONS

Tietje TM, Davis AB, Rivey MP. Comparison of two methods of local anesthetic-based injection as part of a multimodal approach to pain management after total knee arthoplasty. J Pharm Practice 2014. Accepted for publication June 2014.

Aikens GB, Osmundson JR, Rivey MP. New oral pharmacotherapeutic agents for venousthromboprophylaxis after total hip arthroplasty. World J Orthop 2014; 5:188-203. Invited review. Published online July 2014. http://dx.doi.org/10.5312/wjo.v5.i3.188

Rivey MP, Allington DR. Gastrointestinal Infections with Enterotoxigenic Bacterium. Cases 146 &147. ASHP’s PharmPrep 5th Edition, Ginsburg DB, editor, American Society of Health-System Pharmacists, Bethesda, MD. 2013. Accepted for publication.

Allington DR, Rivey MP. Multiple sclerosis (MS) in a primary care setting: Employing strategiesfor improved patient outcomes. Invited continuing education (CE) program for ScientiaCME. Program included Powerpoint slide set with audio presentation, CE post-test questions, and recommendation for future program. Nov 2013.

Tietje TM, Allington DR, Rivey MP. Alemtuzumab: A place in therapy for multiple sclerosis. Int J Clin Med 2013;4:459-71. Published online October 2013 http://dx.doi.org/10.4236/ijcm.2013.410082

Allington DR, Davis A, Sutton J, Rivey MP. Multiple Sclerosis: Fundamental concepts and clinicalperspectives. Book chapter 22 for Advances in Viral Research II. iConcept Press LTD. ISBN: 978-1477555-04-0. Sept 2013.

Aikens GB, Rivey MP, Hansen CJ. Primary venous thromboembolism prophylaxis in ambulatory cancer patients. Ann Pharmacother 2013;47:198-209. Published online February 5, 2013.doi 10.1345/aph.1R335

Nwankwo E, Allington DR, Rivey MP. Emerging oral immunomodulating agents- focus onteriflunomide for the treatment of multiple sclerosis. Degenerative Neurological and Neuromuscular Disease 2012; 2:15-28.

http://dx.doi.org/10.4236/ijcm.2013.410082

https://messaging.umt.edu/owa/redir.aspx?C=n87gQm39QEqJ3-5p5ygBIbJifXp9cNEII6_ydSKJj81uC6OZDNuhhQOD46uMvMtbl-F7xPH59EY.&URL=http%3A%2F%2Fdx.doi.org%2F10.5312%2Fwjo.v5.i3.188


Publications (continued):

Summerday NM, Brown SJ, Allington D, Rivey MP. Vitamin D and Multiple Sclerosis: Review of apossible association. J Pharm Practice 2012:25:75-84. e-publication in October 2011. doi: 10.1177/0897190011421839

Rivey MP. Anticoagulation Therapy: A Point-of-Care Guide (book review). Ann Pharmacother2011; 45:1034-5. Published online July 5, 2011. DOI 10.1345/aph.1Q188

Rivey MP. Pharmacotherapy Principles & Practice, 2nd edition (book review). Ann Pharmacother2010; 44: 2042. Published online Nov 23, 2010. DOI10.1345/aph.1P485

Barten LJ, Allington DR, Procacci KA, Rivey MP. New approaches in the management of multiplesclerosis. Drug Design, Development and Therapy 2010:4:1-23.

Rivey MP, Allington DR. Gastrointestinal Infections with Enterotoxigenic Bacterium. Cases 146 &147. ASHP’s PharmPrep 4th Edition, Ginsburg DB, editor, American Society of HealthSystem Pharmacists, Bethesda, MD. 2010. Published as online cases.

Barten LJ, Allington DR, Procacci KA, Rivey MP. Natalizumab update: a story of benefit andrisk. Drug Discovery Today: Therapeutic Strategies 2009. DOI 10.1016/j.ddstr.2009.10.002

Korenke AR, Rivey MP, Allington DR. Sustained-release fampridine for symptomatic treatment ofmultiple sclerosis. Ann Pharmacother 2008;42:1458-65

Rivey MP, Allington DR. Gastrointestinal Infections. Cases 146 & 147. ASHP’s PharmPrep 3rd Edition, Ginsburg DB, editor, American Society of Health System Pharmacists, Bethesda, MD. 2007.

Allington DR, Rivey MP. Gastrointestinal infections. Case 147. ASHP’s PharmPrep 3rd Edition, Ginsburg DB, editor, American Society of Health System Pharmacists, Bethesda, MD. 2007.

Patrick BN, Rivey MP, Allington DR. Acute renal failure associated with vancomycin- andtobramycin-laden cement in total hip arthroplasty. Ann Pharmacother 2006;40:2037-42.

Colucci VJ and Rivey MP. Potential contribution of long-term rofecoxib in a patient withcardiogenic syncope and ischemic stroke. J Pharm Technol 2006;22:174-8.

Keeley KA, Rivey MP, Allington DR. Natalizumab in the treatment of multiple sclerosis andCrohn’s disease. Ann Pharmacother 2005;39:1833-43.

Rivey MP, Allington DR, Mathis JB. Evaluation of a risk assessment approach to venousthromboembolism (VTE) prophylaxis in medically ill patients. Pharmacotherapy2005;25:1502 (abstract).



Brophy DF, Dougherty JA, Garrelts JC, Parish RC, Rivey MP, Stumpf JL, Taylor CT, Mathis AS.Venous thromboembolism prevention in acutely ill nonsurgical patients. Ann Pharmacother2005;39:1318-24.

Keeley KA, Mathis JB, Rivey MP. Medication Reconciliation in Hospitalized Patients. The NewMontana Pharmacist 2005; summer issue: pp 6-7. (nonrefereed)

Rivey MP, Allington DR. Gastrointestinal infections with enterotoxigenic bacterium. Cases 146. pp 96-98. ASHP’s PharmPrep 2nd Edition, Ginsburg DB, editor, American Society of Health System Pharmacists, Bethesda, MD. 2004

Rivey MP, Allington DR. Gastrointestinal infections with enterotoxigenic bacterium. Cases 147. CD medium. ASHP’s PharmPrep 2nd Edition, Ginsburg DB, editor, American Society of Health System Pharmacists, Bethesda, MD. 2004

Rivey MP, Beall HD, Woolley D, Brand P, Ganser A, James W. Investigation of intraarticular bupivacaine in major orthopedic surgery for postoperative pain control. Pharmacotherapy 2001;21:366-7 (abstract).

Allington DR, Rivey MP. Quinupristin/dalforpristin: A therapeutic review. Clin Ther 2001;23:24-44.

Struckman DR, Rivey MP. Combined therapy with an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor in heart failure. Ann Pharmacother 2001;35:242-8.

McHugh M, Allington DR, Rivey MP. Combination aspirin and dipyridamole & secondary strokeprevetion. Montana Pharmacist 2000;24(No.3):6-7. (not refereed)

Carter JT, Allington DR, Rivey MP. Medical rehabilitation clerkship experience for Pharm.D. students. Am J Pharm Educ 2000;64:96S (abstract).

Colucci VJ, Rivey MP. Tolterodine-warfarin drug interaction. Ann Pharmacother 1999;33:1173-6.

Messer KG, Rivey MP. Feasibility study for pharmacist-directed asthma management in a pediatric practice. Pharmacotherapy 1999;19:521 (abstract).

Rivey MP, Allington DR, Henry Dunham AL. Necrotizing fasciitis associated with nonsteroidal antiinflammatory drug use. J Pharm Technol 1998;14:58-62.

Rivey MP. Pharmacist-managed drug therapy protocols at Community Medical Center. MSHP Newsletter 1997;6(No.3):3-5. (not refereed)

Stone JD, Rivey MP, Allington DR. Nitroprusside treatment of erythromelalgia in an adolescent female. Ann Pharmacother 1997;31:590-2.



Rivey MP, Wood RD, Allington DR, Stratton TP, Erickson CC, Stenson TA. Pharmacy-managed protocol for warfarin use in orthopedic surgery patients. Am J Health-Syst Pharm 1995;52:1310-6.

Rivey MP, Allington DR, Stone JD, Serfoss ML. Alteration of carbamazepine pharmacokinetics in patients with traumatic brain injury. Brain Injury 1995;9:41-7.

Allington DR, Rivey MP. Multiple Sclerosis: An overview. American Pharmacy 1994, accepted for publication, but never published.

Rivey MP, Wood RD, Allington DR, Erickson CC. Evaluation of CoumadinR Protocol in Orthopedic Surgery Patients. Pharmacotherapy 1993;13:272 (abstract). Report in HospFormulary Oct 1993.

Rivey MP and Peterson JP. Pharmacy-managed, weight-based heparin protocol in a small hospital. Am J Hosp Pharm 1993;50:279-84. Report in Clinical Digest Series

Rivey MP, Allington DR, Stone JD. Evidence for alteration of carbamazepine pharmacokinetics during chronic therapy in patients with closed head injury. Pharmacotherapy 1992;12:505 (abstract). Report in CA/CTF.

Rivey MP, North GL, Harper DA, Cochran TG, Simmerman J. Evolution of a neonatal gentamicin dosing protocol in a small community hospital. J Perinatol 1992;12:346-53.

Rivey MP. Hepatitis: A viral alphabet. Montana Pharmacist 1992; 15(3):15-7 (not refereed)

Rivey MP and Stone JD. Carbamazepine hypersensitivity reaction. Brain Injury 1991;5:57-62.

Rivey MP and Peterson JP. Intradermal hepatitis B vaccination. DICP Ann Pharmacother 1991; 25:628-34.

Rivey MP. The School of Pharmacy self-study: What was it, and what did it say? Montana Pharmacist 1991;14:17-9. (not refereed)

Rivey MP. Psychotropic medication and falls in the elderly. Montana Pharmacist 1991;14:24-6. (not refereed)

Rivey MP, Morin LJ, Haakenson P. Attitudes of first-year pharmacy students and preceptors to a "mini-externship" in hospital and community pharmacy practice. Am J Pharm Educ

1990;54:146-9.

Rivey MP. Warfarin: New developments for an old drug. Montana Pharmacist 1990;13(1);11-4. (not refereed)



Freeman D, Cochran G, Rivey M. Search for alterations in red blood cell enzymes in Alzheimer's Disease (abstract). Proc Mont Acad Sci 1989;49:165.

Rivey MP, Taylor JW, and Mullenix TA. TMP/SMX in renally-impaired patients with P. carinii pneumonia. Drug Intell Clin Pharm 1989;23:687-9.

Rivey MP. The use of technicians in pharmacy: A present perspective. Montana Pharmacist 1988;11:7-8,14. (not refereed)

Berg MJ, Ebert BE, Rivey NP, and Schottelius DD. Utilization of Km for phenytoin dosage after folate addition to patient regimen. Ther Drug Monitor 1987;9:304-305.

Rivey MP, Docktor WJ, and Winship MJ. Aminoglycoside monitoring in the neonate. Drug Intell Clin Pharm 1985;19:908-909.

Taylor JW, Murphy MJ, and Rivey MP. Clinical and electrophysiological evaluation of peripheral nerve function in chronic phenytoin therapy. Epilepsia 1985;26:416-420.

Rivey MP, Alexander MR, and Taylor JW. Dipyridamole: A critical evaluation. Drug Intell ClinPharm 1984;18:869-880.

Taylor JW, Alexander B, Kathol RG, Alexander MR, Ebert B, and Rivey MP. Pharmacokinetic analysis of phenytoin-disulfiram interaction (abstract). Drug Intell Clin Pharm 1984;18:499.

Rivey MP, Schottelius DD, and Berg MJ. Phenytoin-folic acid: A review. Drug Intell Clin Pharm 1984;18:292-301.

Berg MJ, Rivey MP, Vern BA, Fischer LJ, and Schottelius DD. Phenytoin and folic acid: Individualized drug interaction. Ther Drug Monitor 1983;5:389-394.

Berg, MF, Fischer LJ, Rivey MP, Vern VA, and Schottelius DD. Phenytoin and folic acid interaction: A preliminary report. Ther Drug Monitor 1983;5:389-394.

Rivey MP. The Effect of Folic Acid Supplementation on Phenytoin Pharmacokinetics in Seizure Patients. Thesis, University of Iowa, December 1982.

POSTERS/PRESENTATIONS AT NATIONAL & STATE PROFESSIONAL MEETINGS

Rivey MP, Faul M, Chong C, Carter J. Vancomycin pharmacokinetics changes with prolonged therapy. Poster presented to Northwest Pharmacy Convention, Coeur d’ alene, ID. May 2014


Posters/Presentations at National & State Professional Meetings (continued):

Chong C, Rivey M, Allington D, Cady K. Quality assessment of inpatient managed anticoagulation protocol. Poster presented to ASHP Midyear Clinical Meeting, Orlando, FL. December 2013.

Davis A, Tietje T, Roestenburg S, Rivey M, James W, Cady K. Comparison of intraoperativeinjections for sustained analgesia after total knee arthroplasty. Poster presentation toNorthwest Pharmacy Convention, Coeur d’ alene, ID. May 2013

Davis A, Tietje T, Roestenburg S, Rivey M, James W, Cady K. Comparison of intraoperativeinjections for sustained analgesia after total knee arthroplasty. Poster presentation toASHP Midyear Clinical Meeting, Las Vegas, NV. December 2012

Rivey MP, Carter JT, Docktor WJ, Allington DR. Incorporating pharmacy practice facultyattributes into a university-affiliated PGY1 residency. Poster presentation to L.S. SkaggsBiomedical Research Symposium, Denver, CO. September 2012.

Summerday NM, Lyons D, Rivey MP, Cady K. Vancomycin dosing: A review of the efficacy of pharmacist dosing protocol. Poster presentation to ASHP Midyear Clinical Meeting, Anaheim, CA. December 2010.

Barten L, Rivey MP. Implementation of an asthma discharge protocol in a hospital emergencydepartment. Platform presentation to Western States Conference for Residents, Monterey, CA. May 2010

Rivey MP. Osteoarthritis Rx Update. Presentation to Montana Gerontology Society Annual

Conference, Missoula, MT. April 2010

Byrd A, Rivey MP. Presciption drug abuse committee addresses concerns of deaths related toprescription abuse. A review of stored unused medications and disposal. Platformpresentation to Western States Conference for Residents, Monterey, CA. May 2009

Korenke A, Rivey M, Hightower L, Cady K. Osteoporosis screening in a community medical center. Platform presentation to Western States Conference for Residents, Monterey, CA. May 2008

Johnson KM, Rivey MP, Mathis JB. ICU clinical pharmacy services in small hospitals: Afeasibility study. Platform presentation to Western States Conference for Residents, Monterey, CA. May 2007

Patrick B, Rivey M, Mathis JB. Lipid management in at risk patients. Platform presentation to

Western States Conference for Residents, Monterey, CA. May 2006

Patrick BN, Rivey MP, Allington DR, Mathis B. Lipid management in at-risk patients. Posterpresented to 40th ASHP Midyear Meeting. LasVegas. December 2005



Rivey MP, Allington DR, Mathis JB. Evaluation of a risk assessment approach to venousthromboembolism (VTE) prophylaxis in medically ill patients. Poster (refereed) presentedto ACCP Annual Meeting, San Francisco, CA. October 2005.

Rivey MP. Anticoagulation in the orthopaedic patient. Presentation to Second Annual Montana Orthopaedic Conference, Missoula, MT. September 2005.

Rivey MP. NSAIDs Update. Presentation to Second Annual Montana Orthopaedic Conference,Missoula, MT. September 2005.

Rivey MP. Update on Prevention of Venous Thromboembolism. Presented to North ValleyHospital Grand Rounds, Whitefish, MT. February 2005. Sponsored by Aventis, Inc.

Rivey MP. Update on Prevention of Venous Thromboembolism. Presented to Community MedicalCenter CE Education Series, Missoula, MT. January 2005. Sponsored by Aventis, Inc.

Keeley K, Rivey M, Allington D, Mathis B. Pharmacist-conducted medication histories. Posterpresented to ASHP Midyear Clinical Meeting, Orlando, Fl. December 2004.

Rivey MP. Update: Prevention and Treatment of Thrombosis. Presentation to Montana Pharmacy

Association (MPA) Fall Meeting, Whitefish, MT. October 2004. 2 hours.

Rivey MP and Gong WC. Training Residents in Self-Evaluation. Invited presentation to 2004ASHP National Residency Preceptors Conference. Presented two 1.5 hr sessions. San Diego,CA. August 2004

Hunt K and Rivey MP. Evaluation of venous thromboembolism (VTE) prophylaxis in surgical andhospitalized patients. Poster (refereed) presented to ASHP Western States ResidencyConference, Monterey, CA, May 2004.

Rivey MP, Hunt KM, Allington DR. Evaluation of thrombosis risk assessment in surgical patients.Poster (refereed) presented to 2nd ACCP-ESCP International Congress on ClinicalPharmacy, Paris, France, April 29, 2004

Rivey MP, Allington DR, Reinivaara-Hall T, Mathis JB, Miller DC, McKernan JL. Developmentof a Pharmacy Practice residency with a focus in pain management in a small hospital. Poster presented at American Society of Health-Systems Pharmacists (ASHP) Midyear Clinical Meeting, New Orleans, LA, December 2003.

Hunt K, Rivey MP. Evaluation of venous thromboembolism prophylaxis in surgical patients afterthe implementation of a Thrombosis Risk Assessment sheet. Poster presented to ASHP Midyear Clinical Meeting, New Orleans, LA, December 2003.



Carter JT, Allington DR, Rivey MP. Use of concept maps to assess clerkship students’ knowledgeof stroke. Poster presented at American Association of Colleges of Pharmacy (AACP) Annual Meeting, Minneapolis, MN, July 2003.

Carter JT, Miller SJ, Rivey MP. Student performance on negatively versus positively wordedmultiple choice questions in a Therapeutics course. Poster presented at AACP AnnualMeeting, Kansas City, MO, July 2002.

Miller DC, Rivey MP, James W, et al. Effect of non-narcotic analgesics on post-operative use ofnarcotics and antiemetics following major orthopedic surgery. Presented at ASHP Clinical Midyear Meeting, New Orleans, LA, December 2001.

Rivey MP. New drug developments and new indications for existing drugs. Presentation to Montana Pharmacy Association (MPA) Fall Meeting, Lewistown, MT, September 2001.

Cochran TG, Allington DR, Cochran GA, Colucci VJ, Rivey MP, Williams AK. Studentassessment of program outcomes. Poster presented to AACP Annual Meeting, Toronto, Canada, July 2001.

Rivey MP, Beall HD, Woolley D, Brand P, Ganser A, James W. Investigation of intraarticular bupivacaine in major orthopedic surgery for postoperative pain control. Poster presentedto American College of Clinical Pharmacy Spring Practice and Research Forum, Salt LakeCity, UT, April 2001.

Rivey MP. Moderator for Advances in Antithrombotic Therapy session at Montana Society ofHealth-Systems Pharmacists (MSHP), West Yellowstone, MT, October 1999.

Messer KG, Rivey MP. Feasibility study for pharmacist-directed asthma management in apediatric practice. Poster presented at ACCP/ESCP International Congress on ClinicalPharmacy, Orlando, FL, April 1999.

Christianson MA, Rivey MP. Evaluation of neonatal gentamicin protocol serum concentration monitoring revision. Poster presented at student research poster session at ASHP Clinical Midyear Meeting, New Orleans, LA, December 1996.

Rivey MP. Moderator for Management Case Studies session at ASHP Clinical Midyear Meeting, New Orleans, LA, December 1996.

Rivey MP. Asthma Care Update. Presented to MSHP Annual Meeting. Technician Session, Billing, Mt. September 1995.

Rivey MP. Patient Care Issues in the Management of Asthma: A Pharmacist's Focus. Presentation to Montana State Pharmaceutical Assn. Annual Meeting, Helena, Mt. May 1995.



Rivey MP. Clinical Pharmacology Update. Presentation to Montana Dental Hygienists' Association Annual Meeting, Polson, MT. October 1994.

Rivey MP, Wood RD, Allington DR. Overview of CoumadinR Protocol. Poster presented at Montana Society of Hospital Pharmacists (MSHP) Annual Meeting, Anaconda, MT. September 1993.

Rivey MP. Presented "Basic Pharmacokinetics and Pharmacology" to Pharmacy Technician Program, MSHP Annual Meeting, Anaconda, MT. September 1993.

Rivey MP. Presented "Pain Management: New Concepts" to Pharmacy Technician Program, MSHP Annual Meeting, Anaconda, MT. September 1993.

Rivey MP. Pain Management. Presentation to Montana Nurses Assn. (MNA) Annual Meeting, Big Sky, MT. September 1993.

Rivey MP. Depression: New guidelines and new agents. Presentation to MNA Annual Meeting, Big Sky, MT. September 1993.

Rivey MP, Wood RD, Allington DR, Erickson CC. Evaluation of CoumadinR Protocol in orthopedic surgery patients. Poster presented at American College of Clinical Pharmacy (ACCP) Annual Meeting, Reno, NV. August 1993.

Rivey MP. Patient medication history. Presentation to Rocky Mountain Region Dental Hygienists Assn., Billings, MT. May 1993

Rivey MP. Pain management. Presentation to Rocky Mountain Region Dental Hygienists Assn., Billings, MT. May 1993.

Rivey MP, Allington DR, Stone JD, Serfoss ML. Alteration of carbamazepine pharmacokinetics in patients with traumatic brain injury. Poster presented at ACCP Winter Practice Forum, Fort Lauderdale, FL. February 1992.

Rivey MP. What's an INR, and why use it? Presented as part of "Clinical Pearls" presentation to MSHP Annual Meeting, Great Falls, MT. September 1992.

Rivey MP. Montana Affiliated State Chapter history presentation. Poster presented to American Society of Hospital Pharmacists (ASHP) Annual Meeting, Washington, D.C. June 1992.

Rivey MP and Peterson JP. Comparison of pharmacy-managed weight-based heparin protocol

with a nursing-managed fixed-dose heparin protocol in a small hospital. Poster presented to ASHP Clinical Midyear Meeting, New Orleans, LA. December 1991.

Allington DA and Rivey MP. Pharmacy services in a rehabilitation unit. Poster presented to ASHP Clinical Midyear Meeting, New Orleans, LA. December 1991.



Woon JL and Rivey MP. Activities of the Montana Society of Hospital Pharmacists. Poster presented to ASHP Clinical Midyear Meeting, New Orleans, LA. December 1991.

Rivey MP. Moderator for Management Case Studies session. ASHP Midyear Clinical Meeting, New Orleans, LA. December 1991.

Rivey MP. Neonatal gentamicin protocol in a Montana hospital. Presentation to MSHP Spring Meeting, Kalispell, MT. May 1991.

Rivey MP. Medications and falls in the elderly. Presentation to Montana Gerontology Society Annual Conference, Anaconda, MT. April 1991.

Chigurupati R, Rivey M, and Cochran T. Delivery of triazolam and baclofen by gastrostomy tube. Poster presented at Montana Academy of Sciences Annual Meeting, Billings, MT. April 1991.

Freeman D, Rivey M, Cochran G. Enzyme alterations and update on Alzheimer's disease. Poster presented at Montana Academy of Sciences Annual Meeting, Billings, MT. April 1991.

Rivey MP, North GL, and Cochran TG. Evolution of a neonatal gentamicin dosing protocol in a small community hospital. Presentation to ASHP Clinical Midyear Meeting, Las Vegas, NV. December 1990.

Allington, DR and Rivey, MP. Drug Usage Evaluation: Sucralfate. Poster presented at MSHP Annual Meeting, Bozeman, MT. September 1990.

Rivey, MP, and Peterson JP. Full-dose heparin: Comparison of pharmacy-managed weight-based protocol with nursing-managed fixed-dose protocol. Poster presented at MSHP Annual Meeting, Bozeman, MT. September 1990.

Rivey MP. Medication in the rehabilitation setting. Presentation to Region VIII Rehabilitation Continuing Education Program, Missoula, MT. June 1990.

North GL, Rivey MP, and Cochran TG. Retrospective study to evaluate the empirical dosing schedule of gentamicin in neonates. Poster presented at ASHP Clinical Midyear Meeting, Atlanta, GA. December 1989.

Rivey MP, Morin LJ, and Haakenson P. Attitudes of first-year pharmacy students and preceptors to a "mini-externship" in hospital and community pharmacy practice. Poster presentation to 49th International Congress of Pharmaceutical Sciences of F.I.P., Munich, West Germany. September 1989.

Rivey MP. Urinary tract infections in the elderly. Montana Gerontology Society Annual Meeting, Billings, MT. April 1989.



Medora M and Rivey MP. The impact of drugs on nutrition states. Presentation to Montana Conference on Developmental Disabilities, Missoula, MT. October 1987.

Rivey MP. Antibiotic drug utilization review. Presentation and panel participation presented to MSHP Annual Meeting, Billings, MT. October 1985.

Rivey MP. Antibiotic drug use review. Presentation to Infection Control Symposium, Missoula, MT. March 1985.

Taylor JW, Alexander B, Kathol RG, Alexander MR, Ebert BE, and Rivey MP. Pharmacokinetic analysis of the phenytoin-disulfiram interaction. Presentation to ACCP Annual Meeting, San Diego, CA. June 1984.

Taylor JW, Murphy M, and Rivey MP. Clinical and electro-physiological evaluation of peripheral nerve function in chronic phenytoin patients. Poster presentation at 18th ASHP Midyear Clinical Meeting, Atlanta, GA. December 1983.

Rivey MP. The effect of folic acid supplementation on phenytoin pharmacokinetics in seizure patients. Presentation to Midwestern Residents Conference, Omaha, NE. May 1982.

GRANT ACTIVITIES

Project Director of Grants in role of Department Chair Joint Sponsorship of Pharmacy Resident Positions (4): approx $265,000 yearly Joint Sponsorship of Assistant Professor at Providence St. Patrick Hospital:

approximately $32,000 yearly Montana Medicaid Outpatient Drug Formulary: approximately $32,000 yearly

Proposal: Measure of impact of informatics in medication administration. Rivey MP, Reinivaara-Hall T, Douglas J. Submitted July 2001 to National Institutes of Health RFA:HS-01-006 grant program. $1,155,860. Not funded.

Proposal: Investigation of intraarticular bupivacaine in major orthopedic surgery for postoperative pain control. Rivey MP and Beall HD. Submitted October 2000 to Univ. of Montana Small Grants Program. $4625. Not funded.

Proposal: Determination of the blood levels of bupivacaine associated with intraarticular use in major orthopedic surgery. Rivey MP, Woolley D, Beall H, Brand P. Submitted November 1999 to Univ. of Montana Small Grants Program. $5000. Not funded. Submitted to Astra-Zeneca Pharmaceuticals, December 1999. $6160. Not funded.


Grant activity, continued:

Proposal: Pharmacy-based approach to community pain education. Carter JT (PI), Rivey MP, Cochran GA, Torma LM. Submitted April 1999 to Dept Health & Human Services. $159,111. Not funded.

Proposal: Pharmacist-directed asthma clinic in a physician practice. Messer KG, Rivey MP. Funded by Merck as general grant to support project $500 x 2. Spring 1999. Project complete.

Proposal: Evaluation of neonatal gentamicin protocol revision. Rivey MP and Christianson MA. Funded by Zeneca as general education grant to support student research project. $500 in November 1996. Project complete.

Proposal: Investigation of CoumadinR Protocol for prevention of thromboembolic disease in patients undergoing major orthopedic surgery. Rivey MP and Erickson C. Funded by Upjohn Company as student research project for $500 in February 1992 and additional $300 in April 1993. Project complete.

Proposal: Investigation of altered carbamazepine pharmacokinetics in rehabilitation patients with traumatic brain injury. Submitted to University of Montana Small Grants Program, October 1992. Not funded.

Proposal: Sorption of drugs to gastric feeding tubes. Cochran TG and Rivey MP. Submitted to University of Montana Small Grants Program, February 1991. Project not funded March 1991.

Proposal: Investigation of intradermal hepatitis B vaccination. Risi G, Rivey M, and Frazier J. Submitted to SmithKline Beecham for $5000, January 1991. Funded by SKB for $1500 in March 1991. Project completed.

Proposal: Rural training of health professionals regarding use of psychotropic drugs in the elderly population. Rivey MP and Docktor WJ. Project proposal submitted to MUAPS as part of Rural Training Center grant in April 1990. Not incorporated in grant proposal.

Proposal: Investigation of the delivery of crushed medication administered by gastrostomy tube (G-tube). Cochran TG, Rivey MP, and Rao N. Funded by Upjohn Company for $3000 received January 1990. Completed in 1991.

Proposal: Investigating alterations of leukotriene receptors in diabetes and asthma. Freeman DS, Rivey MP, and Miller SJ. Funded by University Small Grants Program for $1989 in January 1990. Project funding surrendered by principle investigator in 1991.

Proposal: Compatibility of aminophylline infusion with various antibiotics at simulated Y-injection sites of intravenous administration sets. Rivey MP. Project for $2020 submitted to University Small Grants Program, February 1989. Project not funded, April 1989.


Grant activity, continued:

Proposal: Identification and management of hypercholesterolemia in school age children. Medora M, Cox C, Hardy B, and Rivey MP. Funded by Upjohn Company, January 1989 for $2000. Completed in 1990.

Proposal: Retrospective evaluation of neonatal gentamicin dosing in a community hospital. Rivey MP and North GL. Student research project funded by Upjohn Company, October 1988 for $700; additional $300 in December 1989.

Proposal: Search for alterations in red blood cell enzymes in Alzheimer's Disease. Freeman D (principle investigator), Cochran G, Rivey M, and Docktor WD. Funded 1987 for $2600. Completed in 1990.

MULTICENTER RESEARCH PARTICIPATION

Medication Utilization Evaluation, Novation, through VHA hospital group. 1999 to 2005. Various MUE projects.

1988 to 1996. Drug Surveillance Network DSN), SUNYAB.

* Participant- "Adverse drug reaction reporting in hospitals." Drug Surveillance Network (DSN), SUNYAB, Buffalo, NY. 1994. Ann Pharmacother 1995;29:140-5.

* Participant- "Risk factors for upper gastrointestinal bleeding." DSN. 1993

* Participant- "Patients at risk of gram-negative sepsis." DSN. 1991-1993

* Participant - "Nationwide surveillance of antifungal agents." DSN. 1991. Ann Pharmacother 1994;28:261-70.

* Participant - "Cost effectiveness of ciprofloxacin." DSN. 1990. DICP, Ann Pharmacotherapy 1991;25:857-62.

* Participant - "Adverse effects of antibiotics in high risk patients." DSN. 1989. Ann Pharmacother 1994;28:515-22

* Participant - "Nationwide survey of antibiotic utilization in bacterial pneumonia." DSN. 1989. DICP Ann Pharmacother 1990;24:122


ADVISORY BOARD PARTICIPATION

Invited participant: Health Professions Tour, U.S. Air Force. San Antonio, Tx. May 2010

Invited External Examiner for Pharmacy Program Final Examinations, The University of the West Indies, Trindad. May 2008

Invited participant for symposium “ACS 2004” sponsored by Aventis Inc. Chicago, IL Sept 17-19, 2004. One of approximately 30 pharmacists of total 150 physicians and pharmacists invited nationwide.

Invited consultant. Aventis Pharmaceuticals. “Case-Based Consultants Meeting,” Monterey, CA June 6-8, 2002.

Appointed to as Speaker Faculty Member for Advancing Into a New Era of Anticoagulant Therapy. Program sponsored by John Hopkins University, supported by unrestricted educational grant from AstraZeneca Pharmaceuticals LP. October 2003.

Aventis Pharmaceuticals. Clinical Advisory Board and Invited Consultant. Martha’s Vineyard, MA, July 2000; Palm Springs, CA, April 2000; Tucson, AZ January 2000; Carlsbad, CA July 2001; Monterey, CA June 2002.

Joint Investigational Review Board (JIRB) for Missoula hospitals: CMC representative. 2000 to present

LovenoxR Consultant Board for Rhone-Poulenc: 99. Invited participant to consultants meeting, February 1999, Phoenix, Arizona.

Northwest Anti-Infective Consultant Board for Bristol-Myers Squibb: 95-96

Clinical Pharmacy Neurology Board, Rhone-Poulenc Rorer: 96


MANUSCRIPT REVIEW

Annals of Pharmacotherapy (previously DICP): 1985, 1986, 1992, 1993, 1994, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014

appointed to Editorial Board: Panel on Internal Medicine in 2003-present

Journal of Pharmacy Practice: 2013Journal of Pharmacy Practice and Research: 2007

Book chapter review for Drug-Induced Diseases: Prevention, Detection, and Management. Published by ASHP in 2005

chapter on “Stroke” chapter on “Drug-Induced Visual Disturbances

Amer, J. of Pharmaceutical Education: 1990, 1991, 1992, 1993, 1994, 1995, 1996, 2001, 2002

Amer. J. of Health-System Pharmacists: 1994, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2009, 2011

Journal of Pharmacy Technology: 1995, 1996, 1997Perceptual and Motor Skills: 2002Expert Opinion on Pharmacotherapy: 2009CNS Drugs (ADIS): 2010

PRESENTATIONS TO LOCAL PROFESSIONAL GROUPS: (Last 10 years)

Rivey MP. Rifaximin for hepatic encephalopathy. Presented to Community Medical Center “For Your Drug Information” Professional Education Series. Missoula, MT. February 2011

Rivey MP. Gout Management: The latest (and greatest?) in treatment options. Presented to Community Medical Center “For Your Drug Information” Professional Education Series. Missoula, MT. March 2010 Rivey MP. Current Concepts on Use of Antithrombotic Agents in Stroke. Presented to Community Medical Center Professional Education Series, Missoula, MT. March 2009.

Rivey MP. Anticoagulation in the orthopaedic patient. Presentation to Second Annual Montana Orthopaedic Conference, Missoula, MT. September 2005.

Rivey MP. NSAIDs Update. Presentation to Second Annual Montana Orthopaedic Conference, Missoula, MT. September 2005.


Presentations to Local Professional Groups, continued

Rivey MP. Presented journal club to physicians at St. Patrick Hospital. Average of 2-3 times yearly since 1992

Rivey MP. Update on Prevention of Venous Thromboembolism. Presented to Marcus DalyHospital CE series, Hamilton, MT. October 2005. Sponsored by Sanofi-Aventis, Inc.

Rivey MP. Update on Prevention of Venous Thromboembolism. Presented to North Valley Hospital Grand Rounds, Whitefish, MT. February 9, 2005. Sponsored by Aventis, Inc.

Rivey MP. Update on Prevention of Venous Thromboembolism. Presented to Community Medical Center CE Education Series, Missoula, MT. January 26, 2005. Sponsored by Aventis, Inc.

Rivey MP. Establishing a Pharmacy Residency. Presented to UM Clinical Instructors’ Meeting, Univ. of Montana, Missoula. September 12, 2003

Rivey MP. Invited participant & speaker for program “Advancing Into a New Era of Anticoagulant Therapy” Program Sponsored by: The Johns Hopkins University School of Medicine and the University of Tennessee College of Pharmacy. Supported by grant from AstraZeneca Pharmaceuticals. One of 56 national speakers for program.

September 18-19, 2003. Speaker Review Meeting, Chicago, Ill. participantDecember 17, 2003. Speaker for program. Seattle, WA 1.5 hoursMarch 3, 2004 Speaker for program. Missoula, MT 1.5 hoursMarch 16, 2004 Speaker for program, Spokane, WA 1.5 hours

PRESENTATIONS TO PHARMACY CONTINUING EDUCATION: (Last 10 years)

Rivey MP. Update on Hepatitis C Management. Presented HS 389 Recent Advances in Clinical Medicine: Infectious Diseases course/CE series. University of Montana, Missoula, MT. 3/28/2013.

Rivey MP. New Protease Inhibitors in the Treatment of Chronic Hepatitis C (HCV). Presented to the University of Montana Pharmacy Continuing Education Programs. VIDYO 1 hour, Missoula, MT 3/4/2012.

Rivey MP. New Biologic Response Modifiers in the Treatment of Rheumatoid Arthritis. Presented to the University of Montana Pharmacy Continuing Education Programs. METNET 1 hour, Missoula, MT 3/6/2011.

Rivey MP. Update on the Prophylaxis of Gout: Febuxostat. Presented to the University of Montana Pharmacy Continuing Education Programs. METNET 1 hour, Bozeman, MT 3/7/2010

Rivey MP. Asthma: Diagnosis and Severity Classification METNET (11 sites) 1 hour, Missoula, MT, 4/6/2004.


Presentations to Pharmacy CE, continued

Rivey MP. Update in Anticoagulation. Presented to the University of Montana Pharmacy Continuing Education Programs. METNET (11 sites) 1 hour, Missoula, MT. 2/29/2004

Rivey MP. Advances in the treatment of chronic viral hepatitis. Presented to University of Montana Pharmacy Continuing Education Programs (PCEP), 1 hour

- Bozeman, other sites via METNET 2/23/2003

CREATIVE PROFESSIONAL ACTIVITIES

Developed/implemented first Pharmacy Residency Program in Montana; joint project between UM Pharmacy Practice Dept. and Community Medical Center and then St. Patrick Hospital in 2007. Have served as Residency Program Director since inception. Coordinate preceptors and all rotations (approximately 40 weeks of physician rounding) as well as oversee major residency project at CMC site and work with SPH site coordinator.

Jul 2001 First pharmacy resident

Jan 2003 Preparation of self-study of residency for accreditation site visit (approx. 150 pages)

Jun 2003 Accreditation visit with conditional accreditation granted

Aug 2003 Preparation of response to site visit evaluation (86 pages)

Mar 2004 Accreditation granted

Dec 2006 Preparation of accreditation progress report ((approx 100 pages)

Jul 2007 First resident at St. Patrick Hospital site

Aug 2008 Preparation of self-study for reaccreditation (approx. 250 pages)

Oct 2008 Re-Accreditation visit

Dec 2008 Preparation of response to site visit/rogress report

Mar 2009 Reaccreditation based on 1 year progress report

Dec 2009 Preparation of progress report

Mar 2010 Reaccreditation continuation, based on progress report at 2 years

July 2010 Addition of second resident position at CMC site

Feb 2013 Creation of residency in Drug Information/Academics at UM

July 2014 Addition of second resident position at SPH site

Development of ambulatory care clinic/Anticoagulation Clinic at CMC: August 2010

Involved in development of clinical pharmacist position in ICU: 2007


Professional activities, continued

Development of clinical pharmacist positions in Pain Management: 1999

Development of pharmacy-managed drug therapy protocols: 1989-present- neonatal gentamicin - heparin- traditional aminoglycoside & vancomycin- once-daily aminoglysoside- orthopedic warfarin - therapeutic warfarin- pain management protocol- warfarin reversal protocol with vitamin K- antiemetic protocol- thrombosis risk assessment for surgical patients- outpatient anticoagulation protocol

Development of protocol for pharmacist-managed outpatient warfarin clinic: 1995

Development of numerous standing order protocols: 1984-present

Development of numerous case studies, for various purposes: 1984-present

Development of course materials for distance learning by video: 1995-96, 98-99

Course in Lotus Learning Space for distance learning by computer: 1997-1999Development of course materials for distance learning by Blackboard computer program: 2003-2005

Creation/development of clinical pharmacist position in Rehab. Medicine at CMC: 1991

PROFESSIONAL MEETINGS: (Last 5 years)

Attended 28th Pharmacy Invitational Conference on Antithrombotic Therapy (PICAT). Orlando, Fl. Dec 2013

Attended ASHP Midyear Clinical Meeting, Orlando, Fl. Dec 2013

Attended ACCP Annual Meeting, Albuquerque, NM. October 2013

Attended NW Pharmacy Convention, Coeur d’Alene, ID. Jun 2013

Attended Western States Residency Conference, San Diego, CA. May 2013

Attended ASHP Midyear Clinical Meeting, Las Vegas, NV. Dec 2012


Professional Meetings, continued

Attended 21st Pharmacy Invitational Conference on Antithrombotic Therapy (PICAT). Las Vegas, NV. Dec 2012

Attended NW Pharmacy Convention, Coeur d’Alene, ID. Jun 2012

Attended Western States Residency Conference, Monterey, CA. May 2011

Attended ASHP Midyear Clinical Meeting, New Orleans, LA. Dec 2011

Attended ASHP Midyear Clinical Meeting, Anaheim, CA. Dec 2010

Attended 21st Pharmacy Invitational Conference on Antithrombotic Therapy (PICAT). Anaheim, CA. Dec 2010

Attended Western States Residency Conference, Monterey, CA. May 2009

Attended ASHP Midyear Clinical Meeting, Las Vegas, NV. Dec 2009

Attended 22nd Pharmacy Invitational Conference on Antithrombotic Therapy (PICAT). Las Vegas, NV. Dec 2009

PROFESSIONAL LICENSES

Montana, 1984-PresentCalifornia, 1977-PresentIowa, 1975-PresentArizona, 1975-78 (inactive)

AFFILIATIONS AND SOCIETIES

American Society of Health-Systems Pharmacists (ASHP)Recognized as Fellow (FASHP) in 2008

American College of Clinical Pharmacy (ACCP)Montana Pharmacy Association (MPA): created 2001 by merging MPSA & MSHPMontana State Pharmaceutical Association (MSPA)Montana Society of Health-Systems Pharmacists (MSHP)

President: 1991-2President-elect: 1990-1Upjohn Hospital Research Award committee, Chair: 1988-89, 1989-90, 1990-91, 1991-92Spring Program Committee: 1990, 1992Secretary: October 1986-1988.President-Elect candidate: 1988Nominations and awards committee, Chair 1988-89Fall Program Committee (social subcommittee): October 1988Design & completion of MSHP poster: October 1988, 1992


RECOGNITION/BOARD CERTIFICATION

Pharmacy Faculty Member of the Month: Nov 2012; Sept 2006; Dec 2001; Dec 1994; Oct 1999Recertification as Board Certified Pharmacotherapy Specialist: 2012, 2006, 1999Recognized as Clinical Pharmacist Practitioner by Montana Board of Pharmacy: 2012Granted Fellow status in American Society of Health-System Pharmacists: June 2008Faculty Member of the Year, Pharmacy Practice Dept. 2006-07Faculty Merit Award, University of Montana, 2006Appointed Chair of Pharmacy Practice Department, Univ. of Montana, November 2003Clinical Clerkship Instructor of the Year, 2003John Ruffatto Award Winner, Univ. of Montana 2002. Award given annually to one faculty

member who best merges practice in the community business sector with academic teaching.Faculty Merit Award, University of Montana, 2002Montana Health-Systems Pharmacist-of-the-Year, MSHP, 1999Full Professor promotion, University of Montana, 1998Faculty Merit Award, University of Montana, 1995Upjohn Pharmacy Research Award, MSHP, October 1993.Continuous tenure granted, University of Montana, 1992.Pharmacy Faculty Member of the Year, 1991-92.Board Certified Pharmacotherapy Specialist, 1991.Associate Professor promotion, University of Montana, 1991.Faculty Merit Award, University of Montana, 1990.Honorable Mention Winner, Tagamet Investigators Award, September 1988Faculty Merit Award, University of Montana, 1987.

REFERENCES: available on request

Revised: July2014

rivey mp, allington dr, reinivaara-hall t, mathis jb ...€¦ · web viewsyncope and ischemic...

Documents